Welcome to our dedicated page for SANUWAVE Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on SANUWAVE Health stock.
SANUWAVE Health Inc. is a leading provider of noninvasive, biological response activating devices in regenerative medicine. They focus on repairing and regenerating tissue, musculoskeletal, and vascular structures using their PACE™ technology. With a portfolio of products that activate biologic signaling and angiogenic responses, SANUWAVE helps restore the body's natural healing processes and regeneration. Their products are used in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.Rhea-AI Summary
SANUWAVE Health, Inc. announces record-breaking preliminary revenues of $5.7 to $5.9 million for Q1 2024, marking a 51% to 56% increase over Q1 2023. UltraMist revenues surged by over 55%, contributing 95% to total revenues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. announces the hiring of Peter Sorensen as CFO, bringing extensive finance, forecasting, and capital markets experience to drive growth in the wound care business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.03%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. reports record revenues for Q4 2023 and FY 2023, with significant growth in operating income. The company provides strong revenue growth guidance for Q1 2024 and FY 2024. UltraMIST® systems and consumables drive revenue growth, with a focus on profitable expansion. Adjusted EBITDA shows notable improvement, reflecting operational efficiencies. The company aims for rapid, profitable growth in the upcoming year, expecting substantial revenue increases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
Rhea-AI Summary
SANUWAVE Health, Inc. to present Q4 and FY2023 financial results in a live conference call on March 22, 2024. The company, known for its FDA-approved wound care products, invites participants to join the call or access it online. Materials will be available on the company website, with a replay option until April 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. announces stockholders' approval of business combination with SEP Acquisition Corp. at a special meeting. 70.5% of eligible shares voted or abstained, with 99.3% voting 'for' the proposal. CEO Morgan Frank expresses satisfaction with the outcome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.75%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. (SNWV) is holding a special meeting of stockholders on February 21, 2024, to vote on the previously announced merger with SEP Acquisition Corp. Upon closing, the combined company is expected to trade on the Nasdaq Capital Market under the symbol 'SNWV'. Stockholders of record at the close of business on January 10, 2023, will be entitled to vote at the special meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.68%
Tags
Rhea-AI Summary
SANUWAVE Health, Inc. (SNWV) announces record preliminary revenues of $6.6 million to $6.8 million for Q4 2023, representing a 20% to 24% increase over Q4 2022. FY 2023 revenue range was $20.0 million to $20.2 million, a 19% to 20% year-over-year increase. UltraMist product line drove Q4 2023 growth, accounting for approximately 95% of total revenues. CEO Morgan Frank expresses optimism for continued success in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.39%
Tags
-
Rhea-AI Summary
SANUWAVE Health, Inc. (SNWV) announces 3rd quarter 2023 results, with a 19% increase in revenue to $5.0 million, driven by UltraMist® systems and consumables. Gross margin at 71%, operating loss down by $2.0 million. Net loss at $23.7 million due to non-cash losses on derivative liabilities. Recent highlights include a merger agreement with Nasdaq-listed company, hiring of industry veteran Andrew Walko, and focus on rapid, profitable growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.04%
Tags
-
Rhea-AI Summary
SNWV - SANUWAVE Health, Inc. to Host Live Conference Call to Present Q3 2023 Financial Results. The leading provider of next-generation wound care products will present their Q3 2023 financial results in a live conference call on November 10, 2023, at 8:00AM (ET). Participants can access the call via telephone or an instant Call me™ link. A replay will be available through November 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
News
Rhea-AI Summary
SANUWAVE announces preliminary revenues of $4.7M to $4.9M for Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is SANUWAVE Health Inc. known for?
SANUWAVE specializes in noninvasive, biological response activating devices in the regenerative medicine field for tissue repair and regeneration.
What technology does SANUWAVE use in their products?
SANUWAVE's products are based on PACE™ technology, which activates biologic signaling and angiogenic responses.
In which medical areas does SANUWAVE's portfolio find application?
SANUWAVE's products are used in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac conditions.
What is SANUWAVE's financial outlook for the future?
SANUWAVE expects significant revenue growth in 2024, with anticipated revenues over $30 million and a gross margin increase into the mid 70s.
What recent achievement did SANUWAVE announce for Q4 2023?
SANUWAVE announced preliminary revenues of $6.6 million to $6.8 million for Q4 2023, representing a new quarterly revenue record for the Company.
What was the outcome of SANUWAVE's special meeting of stockholders on February 21, 2024?
SANUWAVE stockholders approved the business combination with SEP Acquisition Corp., with 70.5% of all shares eligible to vote participating in the election.
What was SANUWAVE's Q1 2024 revenue performance like?
SANUWAVE announced preliminary revenues of $5.7 million to $5.9 million for Q1 2024, the highest Q1 revenues in company history.
How does SANUWAVE plan to communicate future updates?
SANUWAVE plans to provide business updates via conference calls, with details available on their website for investors to access.
What financial measures does SANUWAVE use to assess its performance?
SANUWAVE uses EBITDA and Adjusted EBITDA to evaluate its operating performance, with a focus on historical and prospective financial performance.
What are SANUWAVE's key areas of research and application for their patented technologies?
SANUWAVE focuses on wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions in applying and researching their patented energy transfer technologies.
SANUWAVE Health, Inc.
OTC:SNWV
SNWV Rankings
SNWV Stock Data
18.34M
406.40M
10.68%
10.06%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
Eden Prairie